CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients

Al Sayed Ahmed,Huda; Raslan,Wasim   Fawzi; Deifalla,Abdel  Halim Salem; Fathallah,Mohammad   Dahmani

doi:10.3892/mco.2019.1850

CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients

Authors:
- Huda Al Sayed Ahmed
- Wasim Fawzi Raslan
- Abdel Halim Salem Deifalla
- Mohammad Dahmani Fathallah
View Affiliations

Affiliations: Pathology and Laboratory Services Department, Johns Hopkins Aramco Healthcare, 1709 Dhahran, Saudi Arabia, Pathology and Laboratory Services Department, Johns Hopkins Aramco Healthcare, 10613 Dhahran, Saudi Arabia, Department of Anatomy, College of Medicine and Medical Sciences, 26671 Manama, Bahrain, Department of Higher Studies, Arabian Gulf University, 26671 Manama, Bahrain
Published online on: April 24, 2019 https://doi.org/10.3892/mco.2019.1850
Pages: 67-76
Copyright: © Al Sayed Ahmed et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hodgkin's lymphoma (HL) is a hematological malignancy characterized by a minority of neoplastic cells outnumbered by tumor‑associated macrophages (TAMs). The overexpression of the CD163 antigen by TAMs is considered to be a significant predictive biomarker for risk stratification. This is likely caused by a genetic single‑nucleotide polymorphism (SNP) at the gene promoter. The aim of the present retrospective case‑control study was to establish a gene expression profile of a specific biomarker for classical HL (CHL) in order to predict the outcome and survival of CHL patients in Saudi Arabia. The protein expression of CD163 on TAMs was studied using immunohistochemistry (IHC). A prognosis index was calculated for the CD163 protein to assess the risk stratification of CHL. Genotyping of selected SNPs of this antigen was performed for 100 CHL cases and controls. The analysis revealed that the CD163 protein expression level was significantly correlated with disease relapse (DR) and overall survival (OS). In addition, the CD163 index threshold (15.0) was found to be significantly correlated with the relapse rate. Among the studied CD163 SNPs, rs75608120 exhibited a significant correlation with the DR rate of CHL patients, but not with OS. The findings of the present study confirmed that CD163 is a specific marker for TAMs, and its overexpression by TAMs is significantly associated with relapse and reduced survival post‑therapy. In addition, a new methodology of indexing CD163 protein expression for HL risk stratification was proposed. Thus, the present study identified a specific predictive molecular and antigenic biomarker for CHL prognosis.

View Figures

View References

1	Rauf MS, Akhtar S and Maghfoor I: Changing trends of adult lymphoma in the kingdom of Saudi Arabia-comparison of data sources. Asian Pac J Cancer Prev. 16:2069–2072. 2015. View Article : Google Scholar : PubMed/NCBI
2	Leukemia and Lymphoma Society, . American Cancer Society Cancer Facts and Figures 2016; GLOBOCAN 2012; ClinicalTrials.gov. CRI grantee progress reports and other CRI grantee documents. 2016, http://www.cancerresearch.org/cancer-immunotherapy/impacting-all-cancers/lymphoma#sthash.9EkuimDH.dpuf 91November 14–2014
3	Al-Madouj AN, Eldali A and Al-Zahrani AS: Ten year cancer incidence among nationals of the GCC states. Gulf center for cancer control and prevention, king faisal specialist hospital and research center. 2011, http://www.moh.gov.bh/Content/Files/Publications/GCC%20Cancer%20Incidence%202011.pdfSeptember 1–2011
4	Cancer Incidence Report Saudi Arabia 2013, . http://www.chs.gov.sa/Ar/HealthCenters/NCC/CancerRegistry/CancerRegistryReports/2013June 1–2016
5	Maggioncalda A, Malik N, Shenoy P, Smith M, Sinha R and Flowers CR: Clinical, molecular, and environmental risk factors for Hodgkin lymphoma. Adv Hematol. 2011:7362612011. View Article : Google Scholar : PubMed/NCBI
6	Al-Diab AI, Siddiqui N, Sogiawalla FF and Fawzy EM: The changing trends of adult Hodgkin's disease in Saudi Arabia. Saudi Med J. 24:617–622. 2003.PubMed/NCBI
7	Piccaluga PP, Agostinelli C, Gazzola A, Tripodo C, Bacci F, Sabattini E, Sista MT, Mannu C, Sapienza MR, Rossi M, et al: Pathobiology of hodgkin lymphoma. Adv Hematol. 2011:9208982011. View Article : Google Scholar : PubMed/NCBI
8	Montes-Moreno S: Hodgkin's lymphomas: A tumor recognized by its microenvironment. Adv Hematol. 2011:1423952011. View Article : Google Scholar : PubMed/NCBI
9	Smith LB: Nodular lymphocyte predominant Hodgkin lymphoma: Diagnostic pearls and pitfalls. Arch Pathol Lab Med. 134:1434–1439. 2010.PubMed/NCBI
10	Carbone PP, Kaplan HS, Musshoff K, Smithers DW and Tubiana M: Report of the committee on Hodgkin's disease staging classification. Cancer Res. 31:1860–1861. 1971.PubMed/NCBI
11	Hasenclever D and Diehl V: A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. N Engl J Med. 339:1506–1514. 1998. View Article : Google Scholar : PubMed/NCBI
12	Canioni D, Deau-Fischer B, Taupin P, Ribrag V, Delarue R, Bosq J, Rubio MT, Roux D, Vasiliu V, Varet B, et al: Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: A study of 59 cases. PLoS One. 4:e63412009. View Article : Google Scholar : PubMed/NCBI
13	Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider B, Gascoyne RD, et al: International prognostic score in advanced-stage Hodgkin's lymphoma: Altered utility in the modern era. J Clin Oncol. 30:3383–3388. 2012. View Article : Google Scholar : PubMed/NCBI
14	Henry-Amar M, Friedman S, Hayat M, Somers R, Meerwaldt JH, Carde P, Burgers JM, Thomas J, Monconduit M and Noordijk EM: Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med. 114:361–365. 1991. View Article : Google Scholar : PubMed/NCBI
15	Roshal M, Wood BL and Fromm JR: Flow cytometric detection of the classical hodgkin lymphoma: Clinical and research applications. Adv Hematol. 2011:3870342011. View Article : Google Scholar : PubMed/NCBI
16	Dunphy CH: Applications of flow cytometry and immunohistochemistry to diagnostic hematopathology. Arch Pathol Lab Med. 128:1004–1022. 2004.PubMed/NCBI
17	Scott DW and Steidl C: The classical Hodgkin lymphoma tumor microenvironment: Macrophages and gene expression-based modeling. Hematology Am Soc Hematol Educ Program. 2014:144–150. 2014. View Article : Google Scholar : PubMed/NCBI
18	Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, et al: Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: A correlative study from the E2496 Intergroup trial. Blood. 120:3280–3287. 2012. View Article : Google Scholar : PubMed/NCBI
19	Mallmann MR, Schmidt SV and Schultze JL: Macrophages in human cancer: Current and future aspects. Atlas Genet Cytogenet Oncol Haematol. 16:765–774. 2012.
20	Ruhrberg C and De Palma M: A double agent in cancer: Deciphering macrophage roles in human tumors. Nat Med. 16:861–862. 2010. View Article : Google Scholar : PubMed/NCBI
21	Ree HJ and Kadin ME: Macrophage-histiocytes in Hodgkin's disease. The relation of peanut-agglutinin-binding macrophage-histiocytes to clinicopathologic presentation and course of disease. Cancer. 56:333–338. 1985. View Article : Google Scholar : PubMed/NCBI
22	Guo B, Cen H, Tan X and Ke Q: Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma. BMC Med. 14:1592016. View Article : Google Scholar : PubMed/NCBI
23	Sud A, Thomsen H, Sundquist K, Houlston RS and Hemminki K: Risk of second cancer in Hodgkin lymphoma survivors and influence of family history. J Clin Oncol. 35:1584–1590. 2017. View Article : Google Scholar : PubMed/NCBI
24	Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, et al: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med. 362:875–885. 2010. View Article : Google Scholar : PubMed/NCBI
25	Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, et al: A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood. 116:e12–17. 2010. View Article : Google Scholar : PubMed/NCBI
26	Gregory AD and Houghton AM: Tumor-associated neutrophils: New targets for cancer therapy. Cancer Res. 71:2411–2416. 2011. View Article : Google Scholar : PubMed/NCBI
27	Wahl LM and Kleinman HK: Tumor-associated macrophages as target for cancer therapy. J Natl Cncer Inst. 90:1583–1584. 1998. View Article : Google Scholar
28	Derenzini E and Younes A: Predicting treatment outcome in classical Hodgkin lymphoma: Genomic advances. Genome Med. 3:262011. View Article : Google Scholar : PubMed/NCBI
29	Barros MH, Segges P, Vera-Lozada G, Hassan R and Niedobitek G: Macrophage polarization reflects T cell composition of tumor microenvironment in pediatric classical Hodgkin lymphoma and has impact on survival. PLoS One. 10:e01245312015. View Article : Google Scholar : PubMed/NCBI
30	Yoon DH, Koh YW, Kang HJ, Kim S, Park CS, Lee SW, Suh C and Huh J: CD68 and CD163 as prognostic factors for Korean patients with Hodgkin lymphoma. Eur J Haematol. 88:292–305. 2012. View Article : Google Scholar : PubMed/NCBI
31	Azambuja D, Natkunam Y, Biasoli I, Lossos IS, Anderson MW, Morais JC and Spector N: Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma. Ann Oncol. 23:736–742. 2012. View Article : Google Scholar : PubMed/NCBI
32	Lau SK, Chu PG and Weiss LM: CD163: A specific marker of macrophages in paraffin-embedded tissue samples. Am J Clin Pathol. 122:794–801. 2004. View Article : Google Scholar : PubMed/NCBI
33	Ritter M, Buechler C, Langmann T, Orso E, Klucken J and Schmitz G: The scavenger receptor CD163: Regulation, promoter structure and genomic organization. Pathobiology. 67:257–261. 1999. View Article : Google Scholar : PubMed/NCBI
34	Harris JA, Jain S, Ren Q, Zarineh A, Liu C and Ibrahim S: CD163 versus CD68 in tumor associated macrophages of classical Hodgkin lymphoma. Diagn Pathol. 7:122012. View Article : Google Scholar : PubMed/NCBI
35	El-Zein R, Monroy CM, Etzel CJ, Cortes AC, Xing Y, Collier AL and Strom SS: Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk. Cancer. 115:1651–1659. 2009. View Article : Google Scholar : PubMed/NCBI